The stock price of BioXcel Therapeutics hit an all-time high on Monday after the company reported final clinical trial results showing its lead drug successfully calmed agitation in patients with schizophrenia and bipolar disorder.
The positive data paves the way for the New Haven company to seek its first FDA approval in early 2021, the company said.